Journal article
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, Sarah Q To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, Lisa-Jane K Graham, Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D Davis, Phillip Parente, Carmel Pezaro, Tilman Todenhoefer, Lisa G Horvath, Arun A Azad
EUROPEAN UROLOGY FOCUS | ELSEVIER | Published : 2021
Abstract
BACKGROUND: The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent years. Identifying predictive and/or prognostic biomarkers in the context of this rapidly expanding therapeutic armamentarium remains a pressing and unmet clinical need. OBJECTIVE: To develop a prognostic whole-blood gene signature for mCRPC patients. DESIGN, SETTING, AND PARTICIPANTS: As part of an ongoing prospective, multicentre biomarker research study (Australian Prostate Biomarker Alliance), we enrolled 115 mCRPC patients commencing chemotherapy (n = 34) or androgen receptor (AR) pathway inhibitors therapy (n = 81) and obtained pretreatment whole-blood samp..
View full abstractGrants
Funding Acknowledgements
Edmond M. Kwan: National Health and Medical Research Council (NHMRC) Postgraduate Scholarship; Sarah Q. To: NHMRC Fellowship; Ian D. Davis: NHMRC Practitioner Fellowship; Carmel Pezaro: Cancer Council Victoria Early Career Seed Grant; Lisa G. Horvath: Astellas Investigator-initiated grant; and Arun A. Azad: NHMRC project grant, Victorian Cancer Agency Clinical Research Fellowship, Astellas Investigator-initiated grant.